Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study-Reference-Cited by-同舟云学术

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study

Published:2019-02-22 Issue:6 Volume:49 Page:506-514
ISSN:1465-3621
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Tomita Yoshihiko¹²,Fukasawa Satoshi³,Shinohara Nobuo⁴,Kitamura Hiroshi⁵⁶,Oya Mototsugu⁷,Eto Masatoshi⁸⁹,Tanabe Kazunari¹⁰,Saito Mitsuru¹¹,Kimura Go¹²,Yonese Junji¹³,Yao Masahiro¹⁴,Uemura Hirotsugu¹⁵

Affiliation:

1. Current affiliation: Department of Urology, Molecular Oncology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata

2. Department of Urology, Yamagata University Hospital, Yamagata

3. Prostate Center and Division of Urology, Chiba Cancer Center, Chiba

4. Department of Urology, Hokkaido University, Sapporn

5. Current affiliation: Department of Urology, University of Toyama, Toyama

6. Department of Urology, Sapporo Medical University Hospital, Sapporo

7. Department of Urology, Keio University Hospital, Tokyo

8. Current affiliation: Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka

9. Department of Urology, Kumamoto University, Kumamoto

10. Department of Urology, Tokyo Women’s Medical University Hospital, Tokyo

11. Department of Urology, Akita University Hospital, Akita

12. Department of Urology, Nippon Medical School Hospital, Tokyo

13. Department of Urology, Cancer Institute Hospital, Tokyo

14. Department of Urology, Yokohama City University Hospital, Yokohama

15. Department of Urology, Kindai University Faculty of Medicine, Osaka, Japan

Funder

Bristol-Myers Squibb

ONO Pharmaceutical Company Ltd

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/49/6/506/28757527/hyz026.pdf

Reference13 articles.

1. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates;Brahmer;J Clin Oncol,2010

2. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade;Iwai;Proc Natl Acad Sci USA,2002

3. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

4. Kidney Cancer Working Group report;Naito;Jpn J Clin Oncol,2010

5. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review;Oh;Int J Oncol,2014

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pregnant patient with Xp11.2/transcription factor E3 translocation renal cell carcinoma: a case report and literature review;Frontiers in Oncology;2024-06-26

2. A novel algorithm to differentiate between primary lung tumors and distant liver metastasis in lung cancers using an exosome based multi gene biomarker panel;Scientific Reports;2024-06-14

3. Exosome derived multi-gene biomarker panel identifies the risk of liver metastasis in lung cancer patients;2023-12-13

4. The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non‐clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group database;Cancer Medicine;2023-10-31

5. Immune regulation and prognosis indicating ability of a newly constructed multi-genes containing signature in clear cell renal cell carcinoma;BMC Cancer;2023-07-12